Cell Matrices in Tissue Engineering

3 Min Read

The search for synthetic-based biocompatible materials has posed particular problems for researchers in that no synthetic material is completely accepted and integrated by the body. Therefore, the goal has been to create a replacement tissue that closely mimics natural tissue and will activate normal body healing and tissue reconstruction, and eventually be resorbed harmlessly into the body after normal healing has begun.

The search for synthetic-based biocompatible materials has posed particular problems for researchers in that no synthetic material is completely accepted and integrated by the body. Therefore, the goal has been to create a replacement tissue that closely mimics natural tissue and will activate normal body healing and tissue reconstruction, and eventually be resorbed harmlessly into the body after normal healing has begun.

Scaffolds used to grow the tissue must be biocompatible, biodegradable, and bioabsorbable and must have a surface chemistry that promotes cell adhesion and growth. They also must have a specific porosity and pore size dependent upon the type of tissue to be grown and be able to degrade within the desired time frame. It must have the capability to be molded into a variety of desired shapes.

 

The goal in bone tissue engineering is to have a composite with surface and microstructural attributes that promote good cell adhesion and vascularization, that have the necessary transport channels for good cell activity, that has the right three-dimensional network to serve as a substitute for bone under both static and dynamic, weight-bearing conditions, and will be resorbed at an appropriate rate—neither too fast nor too slowly. Even titanium, currently considered virtually the gold standard for implant materials (such as replacement hip joints) is not ideal, and eventually shows failure.

A range of bioceramic and polymer scaffold materials developed so far for bone tissue applications include: coralline hydroxyapatite, calcium carbonate, poly(lactic acid) (PLA), poly(glycolic acid) (PGA) and copolymers of PLA and PGA, as well as new polymer systems like poly(propylene fumarate) and polyarylates. Composites have been used to compensate for the fact that no single material has fulfilled all the necessary functions.

Neuronal tissue is notoriously difficult to replace; even when autologous nerves are used, function is at best about 50% of normal. Again various synthetic materials are being investigated for use as scaffolds, including PLLA poly (L-Lactic Acid) and PLGA poly (DL-glycoloic acid). The ideal scaffold will probably be a combination of synthetic and natural materials.


(The above is an excerpt from Report #S520, “Tissue Engineering, Cell Therapy and Transplantation: Products, Technologies & Market Opportunities, Worldwide, 2009-2018.”)

     

Share This Article
Follow:
I serve the interests of medical technology company decision-makers, venture-capitalists, and others with interests in medtech producing worldwide analyses of medical technology markets for my audience of mostly medical technology companies (but also rapidly growing audience of biotech, VC, and other healthcare decision-makers). I have a small staff and go to my industry insiders (or find new ones as needed) to produce detailed, reality-grounded analyses of current and potential markets and opportunities. I am principally interested in those core clinical applications served by medical devices, which are expanding to include biomaterials, drug-device hybrids and other non-device technologies either competing head-on with devices or being integrated with devices in product development. The effort and pain of making every analysis global in scope is rewarded by my audience's loyalty, since in the vast majority of cases they too have global scope in their businesses. Specialties: Business analysis through syndicated reports, and select custom engagements, on medical technology applications and markets in general/abdominal/thoracic surgery, interventional cardiology, cardiothoracic surgery, patient monitoring/management, wound management, cell therapy, tissue engineering, gene therapy, nanotechnology, and others.
Exit mobile version